中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2013年
5期
481-482
,共2页
瑞格列奈%甘精胰岛素%2型糖尿病
瑞格列奈%甘精胰島素%2型糖尿病
서격렬내%감정이도소%2형당뇨병
Repaglinide%Insulin glargine%Type 2 diabetes
目的：比较新诊断2型糖尿病患者应用胰岛素促泌剂瑞格列奈单一治疗及联合长效胰岛素甘精胰岛素治疗12周后血糖水平的差异。方法纳入2012年1月~2013年1月北京军区总医院新诊断2型糖尿病患者48例，随机分为单药治疗组（n=24）及联合治疗组（n=24），单药治疗组仅餐前口服瑞格列奈（初始计量0.5 mg），联合治疗组除餐前服用瑞格列奈外，每晚8 pm皮下注射甘精胰岛素（初始计量6 u）。根据血糖水平调整用药剂量，治疗12周后观察两组空腹静脉血糖（FBG）水平、餐后2小时血糖（2 hPBG）水平、糖化血红蛋白（HbA1c）水平及血糖达标时间。结果与单药治疗组相比，联合治疗组FBG[（5.9±1.6）mmol/L vs.（6.8±1.5）mmol/L]、2 hPBG[（8.8±0.9）mmol/L vs.（9.2±0.8）mmol/L]、HBA1c[（7.4±0.5）% vs.（7.8±1.3）%]均更低，且血糖达标时间明显缩短[（6.1±1.3）d vs.（8.9±2.5）d]。结论胰岛素促泌剂与长效胰岛素联合治疗2型糖尿病初始治疗较单独应用胰岛素促泌剂效果更好，并能促使血糖尽快达标。
目的：比較新診斷2型糖尿病患者應用胰島素促泌劑瑞格列奈單一治療及聯閤長效胰島素甘精胰島素治療12週後血糖水平的差異。方法納入2012年1月~2013年1月北京軍區總醫院新診斷2型糖尿病患者48例，隨機分為單藥治療組（n=24）及聯閤治療組（n=24），單藥治療組僅餐前口服瑞格列奈（初始計量0.5 mg），聯閤治療組除餐前服用瑞格列奈外，每晚8 pm皮下註射甘精胰島素（初始計量6 u）。根據血糖水平調整用藥劑量，治療12週後觀察兩組空腹靜脈血糖（FBG）水平、餐後2小時血糖（2 hPBG）水平、糖化血紅蛋白（HbA1c）水平及血糖達標時間。結果與單藥治療組相比，聯閤治療組FBG[（5.9±1.6）mmol/L vs.（6.8±1.5）mmol/L]、2 hPBG[（8.8±0.9）mmol/L vs.（9.2±0.8）mmol/L]、HBA1c[（7.4±0.5）% vs.（7.8±1.3）%]均更低，且血糖達標時間明顯縮短[（6.1±1.3）d vs.（8.9±2.5）d]。結論胰島素促泌劑與長效胰島素聯閤治療2型糖尿病初始治療較單獨應用胰島素促泌劑效果更好，併能促使血糖儘快達標。
목적：비교신진단2형당뇨병환자응용이도소촉비제서격렬내단일치료급연합장효이도소감정이도소치료12주후혈당수평적차이。방법납입2012년1월~2013년1월북경군구총의원신진단2형당뇨병환자48례，수궤분위단약치료조（n=24）급연합치료조（n=24），단약치료조부찬전구복서격렬내（초시계량0.5 mg），연합치료조제찬전복용서격렬내외，매만8 pm피하주사감정이도소（초시계량6 u）。근거혈당수평조정용약제량，치료12주후관찰량조공복정맥혈당（FBG）수평、찬후2소시혈당（2 hPBG）수평、당화혈홍단백（HbA1c）수평급혈당체표시간。결과여단약치료조상비，연합치료조FBG[（5.9±1.6）mmol/L vs.（6.8±1.5）mmol/L]、2 hPBG[（8.8±0.9）mmol/L vs.（9.2±0.8）mmol/L]、HBA1c[（7.4±0.5）% vs.（7.8±1.3）%]균경저，차혈당체표시간명현축단[（6.1±1.3）d vs.（8.9±2.5）d]。결론이도소촉비제여장효이도소연합치료2형당뇨병초시치료교단독응용이도소촉비제효과경호，병능촉사혈당진쾌체표。
Objective To compare the difference in blood glucose level in the patients with newly diagnosed type 2 diabetes treated with only repaglinide or repaglinide combining insulin glargine for 12 weeks. Methods The patients (n=48) were chosen from the General Hospital of PLA Beijing Military Area Command from Jan. 2012 to Jan. 2013, and randomly divided into repaglinide group and combining group (each n=24). The repaglinide group was orally given repaglinide (0.5 mg initially) before meals and combining group was given oral repaglinide and hypodermic injection of insulin glargine (6 u initially) at every 8 pm. The dosages of the drugs were adjusted according to patients’ blood glucose level. The levels of fasting blood glucose (FBG), 2-hour postprandial blood glucose (2-h PBG) and HbA1C, and control time of blood glucose were observed in two groups after treatment for 12 weeks. Results Compared with repaglinide group, the levels of FBG [(5.9±1.6) mmol/L vs. (6.8±1.5) mmol/L], 2-h PBG [(8.8±0.9) mmol/L vs. (9.2±0.8) mmol/L] and HBA1C [(7.4±0.5)%vs. (7.8±1.3)%] were lower, and control time of blood glucose was shorter [(6.1±1.3) d vs. (8.9±2.5) d] in combining group. Conclusion Repaglinide combining insulin glargine has better curative effect on type 2 diabetes than only repaglinide, which can improve blood glucose reaching normal level.
